• Nasus Pharma interim CFO Oren Elmaliah filed an initial ownership report listing options for 52,140 ordinary shares exercisable at USD 1.23-6.05.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nasus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-043796), on September 23, 2026, and is solely responsible for the information contained therein.